Homepage Top Section2

As part of the agreement terms, UAB has received a non-exclusive licence to leverage the H2L2 Harbour Mice platform of Nona Biosciences for the creation of fully human

Investors for the funding round include Johnson & Johnson Innovation, Deerfield Management, Catalio Capital Management, Braidwell, the Retinal Degeneration Fund, and GV. The company is dedicated to advancing

Following its recent US Food and Drug Administration (FDA) approval, the therapy is now a treatment option for patients aged two years and older with neurofibromatosis type 1

Romvimza is indicated for use in TGCT patients for whom surgery could worsen functional limitations or cause severe morbidity. The approval is based on the results from the

It also focuses on developing the candidate targeting other autoimmune disorders like Lupus Nephritis (LN). The partnership underscores Conduit’s commitment to creating high-quality preclinical data, which will play

Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and

The partnership will utilise the Pb-212 production technology and radionuclide development infrastructure of AdvanCell alongside Lilly’s expertise in drug development and drug candidate programmes. It will support the

In March last year, Fennec Pharmaceuticals entered an exclusive licensing agreement, granting Norgine commercialisation rights for the injection in Australia, New Zealand, and Europe. Under this agreement, Fennec

This expansion includes exclusive distribution agreements as well as new market authorisation transfers. The current agreement in Japan follows the last year agreement between the two companies for